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Abstract Mitochondria are organelles responsible for vital
cell functions. p53 is a transcription factor that regulates the
DNA stability and cell growth normality. Recent studies re-
vealed that p53 can influence mitochondrial function chang-
ing from normal condition to abnormal condition under dif-
ferent stress levels. In normal state, p53 can maintain mito-
chondrial respiration through transactivation of SCO2. When
stress stimuli presents, SCO2 overexpresses and leads to ROS
generation. ROS promotes p53 inducing MALM (Mieap-in-
duced accumulation of lysosome-like organelles within mito-
chondria) to repair dysfunctional mitochondria and MIV
(Mieap-induced vacuole) to accomplish damaged mitochon-
dria degradation. If stress or damage is irreversible, p53 will
translocate tomitochondria, leading into apoptosis or necrosis.
Neurodegenerative diseases including Parkinson’s disease,
Huntington’s disease and Alzheimer’s disease are still lack
of clear explanations of mechanisms, but more studies have
revealed the functional relationship betweenmitochondria and
p53 towards the pathological development of these diseases.
In this review, we discuss that p53 plays the vital role in the
function of mitochondria in the aspect of pathological change
metabolism. We also analyze these diseases with novel
targeted treating molecules which are related to p53 and mi-
tochondria, hoping to present novel therapies in future clinic.
Keywords Mitochondria . p53 .Mitochondrial quality
control . Apoptosis . Mitochondrial dysfunction .
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Introduction
Neurodegenerative diseases are common but hard to cure. At
the same time, the mechanisms still need further study.
Fortunately, recent studies have revealed some relationships
between mitochondria and p53 in the development of neuro-
degenerative diseases. Mitochondria are organelles that are
responsible for several vital cell functions, including respira-
tion, oxidative phosphorylation, and regulation of apoptosis.
Moreover, they are also the main intracellular place for gen-
erating reactive oxygen species (ROS) (Gibellini et al. 2015).
p53 protein is a transcription factor that regulates the DNA
stability and cell growth normality. It can maintain the DNA
stability by inhibiting its mutation. Stresses like DNA damage
will turn on its function, thus, leading to cell cycle arrest for
DNA repair, senescence, cell growth arrest, and therefore,
apoptosis (Chen et al. 2010).
However, the mechanism of mitochondrial and p53 path-
way towards the neurodegenerative diseases haven’t been
clarified clearly.
Further studies have revealed that p53 can destruct the reg-
ulation of mitochondrial function in stress state, which con-
tributes to the abnormal neuronal condition and the occurrence
and development of some neuronal diseases. Based on these
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previous researches, we have some novel insights of the rela-
tionship between mitochondria and p53 especially in the as-
pect of neurodegenerative diseases, hoping to present novel
molecular therapies in future clinic. In this review, we discuss
the influence of p53 upon mitochondria shifting from normal
condition to abnormal condition under different stress levels,
as well as the relations of p53 and mitochondria to etiology
and molecular therapies of three neurodegenerative diseases.
p53 regulates the mitochondrial respiration
In normal condition, p53 can modulate the utilization of mi-
tochondrial respirator. An experiment reported that HCT116
p53+/+ cells have higher oxygen consumption than HCT116
p53−/− cells, suggesting that p53 can regulate mitochondrial
respiratory activity (Bergeaud et al. 2013).
Cytochrome c oxidase (COX) is known as complex IVand plays
the vital role in the respiratory chain. It contains three mitochondrial
DNA encoding subunits and ten nuclear DNA encoding subunits
(Assaily and Benchimol 2006, Yang et al. 2010).
Synthesis of Cytochrome c Oxidase 2 (SCO2) is one of the
nuclear DNA encoding subunits, p53 can binds to the SCO2
promoter in nuclear DNA and regulating mitochondrial respi-
ration. In the experiment of Satoaki Matoba et al., they used
human cancer cells with wild-type p53 represents the p53-
deficient cell. The disruption of the SCO2 gene represent the
metabolic switch towards glycolysis in the p53-deficient cell.
The result shows that p53-deficient cell down regulates the
mitochondrial respiration (Matoba et al. 2006), indicating
the mitochondrial regulation by p53.
Moreover, Jerad Fields et al. demonstrated that SCO2 can
rescue the decreased aerobic respiration in p53-deficient cells
at physiologic levels, confirming that p53 can transactivate the
SCO2 gene (Fig. 1b) (Fields et al. 2007).
However, this binding is not beneficial all the time. To keep
the balance of the respiration and avoid theWarburg effect, the
cells will promote p53 expression and thus, resulting the
SCO2 overexpression (Madan et al. 2013), but ROS will also
be generated during this procedure. Mitochondrial-generated
ROS will induce p53 translocation to nuclear and mitochon-
dria, leading into the Mieap expression and mitochondria me-
diated apoptosis (Qi et al. 2011).
p53 involved mitochondrial quality control: MALM
and MIV
After stress stimuli, p53 will function as to control mitochon-
drial quality. Mitochondrial quality control (MQC) is signifi-
cantly important for maintaining the stable and healthy state of
our bodies. There are two possible mechanisms of the quality
control. The first one is mitophagy, mediated by double-
membraned autophagosomes. The second one is protease-
dependent degradation of damaged proteins in mitochondria.
Moreover, many novel studies confirmed the vital role of the
interaction between p53 and mitochondria towards MQC.
MALM and MIV
Mieap, a p53-inducible protein, was found which has influ-
ence on the MQC in mouse intestinal tumor (Tsuneki et al.
2015) and human colorectal cancer (Kamino et al. 2016),
leading to the repair of mitochondria function.
Accumulation of the oxidized protein was reported to im-
pair the function of the mitochondria, leading to the mitochon-
drial dysfunction. Mieap repairs unhealthy mitochondria by
eliminating the oxidized mitochondrial proteins, including
ATP synthase b-subunit. Therefore, it maintains the quality
of mitochondria (Miyamoto et al. 2011). Besides, Noriaki
Kitamura et al. discovered two novel mechanisms, MALM
(Mieap-induced accumulation of lysosome-like organelles
within mitochondria) and MIV (Mieap-induced vacuole),
and they both contribute to the process of MQC.
In MALM, Mieap-regulated lysosome in mitochondria is
not similar to canonical autophagy. Destruction of the mito-
chondrial structure on electron microscopy and the loss of
mitochondrial signal on immunofluorescence are the character
in mitophagy, but these are not found in MALM (Miyamoto
et al. 2011). Instead, MALM induces intramitochondrial
lysosome-like organella without destroying the mitochondrial
structure, thus, leading to the elimination of oxidized mito-
chondrial proteins and improvement of mitochondrial func-
tions afterwards (Kitamura et al. 2011). During this procedure,
NIX and BNIP3 were found to take the vital role in targeting
and repairing the damaged mitochondria. NIX and BNIP3 are
localized in outer mitochondria membrane, which will be ac-
tivated by the ROS under the stress condition that can also
activate Mieap expression. BH3 domain of activated NIX and
BNIP3 can collect Mieap and interact with its coiled-coil do-
main. With the help of Mieap, NIX and BNIP3 can form a
pore which allows the translocation of the combination of
Mieap and lysosome from cytoplasm to mitochondrial matrix,
leading into the degradation of oxidized protein (Kitamura
et al. 2011). Moreover, another protein 14–3-3γ, a member
of the 14–3-3 family of proteins as well as Mieap-interacting
protein is also demonstrated to take the vital role in MALM.
Takafumi Miyamoto et al. found that 14–3-3γ is translocated
from the cytoplasm to mitochondrial matrix during MALM.
Moreover, further study showed that 14–3-3γ is involved in
decreasing oxidized mitochondrial proteins, which helps to
the function of MALM (Miyamoto et al. 2012) (Fig. 1c).
With enhancement of the stress level, MALM can be
inhibited, MIV degrade the dysfunctional mitochondria by
accumulating lysosomes. It is observed that lysosomes accu-
mulate around the edge of a MIV and fuse to the MIV
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membrane. When the lysosomes are abundant, MIV will
lead to the degradation of the mitochondria. But the
detailed molecular regulation of this mechanism needs
further study.
In conclusion, MALM plays a role in repairing mitochon-
dria, whereas MIV degrade mitochondria. MIV should be
enhanced while MALM is inhibited to maintain the goal of
controlling the mitochondrial quality (Kitamura et al. 2011).
(Fig. 1d).
Mitochondrial p53 translocation and its related
apoptosis and necrosis
When stress or damage is irreversible, p53 will translocate to
mitochondria, leading into apoptosis, necrosis.
Mitochondrial p53 translocation
The detrimental function of p53 translocation
The translocation of mitochondrial p53 contributes to
the cells metabolism changes including changes of mi-
tochondrial membrane potential, oxidative stress, cyto-
chrome c release, and mitophagy, which leads to mito-
chondrial dysfunction afterwards, and therefore, causing
p53-induced apoptosis and necrosis.
Factors to influence mitochondrial p53 translocation
Many factors are found to influence the mitochondrial p53
translocation, including stress, exercise, mitochondrial
uncoupling and DNA damage.
Fig. 1 p53 plays numerous roles in mitochondria-related processes. a
p53 influence towards mitochondria under different stress level. With
the enhancement of stress level, mitochondrial function will switch
from normal to abnormal in the presence of p53. b p53 regulation and
transactivation of mitochondrial Synthesis of Cytochrome c Oxidase 2
(SCO2). The figure shown is the nuclear transactivation of SCO2 by p53.
SCO2 is targeted to the inner membrane of the mitochondria where they
bind to complex IV and promote aerobic respiratory. When the cell is
under the primary stress state, the cells will promote p53 expression
keep the balance of the respiration and avoid the Warburg effect and
thus, resulting the SCO2 overexpression, but ROS will also be
generated during this procedure. c Mieap-induced accumulation of
lysosome-like organelles within mitochondria (MALM). Mieap is a p53
inducible protein. Mitochondrial-generated ROS will induce p53
translocation to nuclear and mitochondria. p53 binds to Mieap promoter
and leads to the Mieap overexpression. Mieap will binds to NIX and
BNIP3, causing the activity change of NIX and BNIP3. These two
protein can form a mitochondrial transition-like pore, permitting the
translocation of Mieap and lysosome complex into mitochondrial matrix,
thus, degenerating ROS and other oxidative protein. d Mieap-induced
vacuole (MIV). With the enhancement of stress level, MALM is
inhibited, Mieap will form a vacuole and degenerate the impaired
mitochondria. Abbreviations: SCO2: mitochondrial Synthesis of
Cytochrome c Oxidase 2, MALM: Mieap-induced accumulation of
lysosome-like organelles within mitochondria, MIV: Mieap-induced
vacuole, ROS: reactive oxygen species, NIX: NIP-like protein X,
BNIP3: BCL2/adenovirus E1B 19 kDa protein-interacting protein 3
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Christine Sansomed et al. found that short term hypoxic
stress induces mitochondrial p53 using isolated mitochondria
shown by electron microscopy. Significant amount of mito-
chondrial p53 induced by stress is located at the surface of the
organelle (Sansome et al. 2001).
Interestingly, acute exercise was demonstrated to reduce
nuclear p53, but it enhances the mitochondrial abundance of
p53. Moreover, endurance exercise can be the signal to local-
ize p53 to the mitochondria (Saleem and Hood 2013).
DNA damage may lead to the translocation of mitochon-
drial p53 is revealed as well (Hernlund et al. 2009).
Besides, FeiWang et al. uncoupled the oxidative phosphor-
ylation by carrying protons across the mitochondrial mem-
brane and detected the p53 of 12-O-tetradecanoylphorbol
13-acetate (TPA) treated cells. Result shows that mitochondri-
al uncoupling can block p53 translocation (Wang et al. 2010).
Regulation of mitochondrial p53 translocation
Among these factors, we highlight the related molecules in
stress state and its pathway of the procedure in mitochondrial
p53 translocation.
It has already been mentioned that cytoplasmic p53 rapidly
translocate to mitochondria in response to a stress signal. This
direct translocation of p53 results in robust mitochondrial out-
er membrane permeabilizing and causing apoptosis.
According to the influence towards apoptosis, proteins on
mitochondria are classified into anti-apoptotic and pro-
apoptot ic protein. Pro-apoptot ic protein contain
Bax、Bak、tBid、Bim 、Puma and Noxa while anti-
apoptotic protein include Bcl-2 family members. In normal
state, Bcl-2 family members combine with Bax and Bak,
inhibiting the apoptotic function of these two proteins. When
stress stimuli presents, p53 will translocate into mitochondrial
outer membrane and binds to Bcl-2 or Bcl-xL, leading into the
release of Bax and Bak. Bax and Bak can form the permeabil-
ity pore respectively, which mediate the mitochondrial dys-
function through the formation of mitochondrial permeability
transition pore (MPTP). Anti-apoptotic and pro-apoptotic pro-
teins interact and localize on the mitochondrial membrane to
keep the balanced state.
After the stress stimuli, mitochondrial p53 accumulation
can be detected (Erster et al. 2004). Nuclear p53 transactivates
its target gene Puma and induce the formation of Puma/Bcl-xL
complex, which could liberate p53 in cytoplasm. In stress
s t a t e , monoub iqu i t i n a t ed p53 can change in to
polyubiquitination state with the help of Murine Double
Minute 2 (MDM2). Polyubiquitinated p53 can switch to
deubiquitination state and translocate to the outer mitochon-
drial membrane, neutralizing the inhibitory function of Bcl-2/
xL in the presence of HAUSP (Herpesvirus Associated
Ubiquitin Specific Protease). Bax and Bak can then be re-
leased and form the pores, leading to the cytochrome c release.
Besides, deubiquitination p53 can interact inner membrane
potential. Complex of cyclophilin D and p53 on inner mem-
brane contribute the permeabilization as well (Fig. 2) (Vaseva
and Moll 2009).
p53 involved apoptosis
As discussed previously, the translocation of p53 may lead to
mitochondrial dysfunction. This change leads to apoptosis
eventually. After stress stimuli, p53 induces MPTP on both
outer and inner membranes. The outer membrane MPTP can
induce cytochrome c release, which is the core factor of
apoptosis.
Besides MPTP, other factors are found to induce apoptosis
as well. Jie Feng et al. found that PUMA (p53 upregulated
modulator of apoptosis) is required for neuronal apoptosis
(Feng et al. 2015). An experiment records that the suppression
of p53 effectively mitigates disease-associated mitochondrial
and dysfunction, thus, decrease the apoptosis (Wang et al.
2014). Besides, NOXA (a kind of apoptosis regulating factor)
was found to mediate the p53-dependent apoptosis through
mitochondrial dysfunction as well. Young-Woo Seo et al. in-
dicated that NOXA seems to cause changes like activating the
permeability transition-related pore, thus, releasing cyto-
chrome c from mitochondria into cytosol (Seo et al. 2003).
Ji Young Le et al. demonstrated that in the presence of p53, 2-
methoxyestradiol (2-MeO-E2) may cause cellular changes,
like reducing the cell viability and enhancing the proportions
of G2/M cells and apoptotic sub-G1 cells, which may induce
the apoptosis (Lee et al. 2014). Moreover, p53 is still be dem-
onstrated as the vital factor in Mn-induced neuronal apoptosis
(Wan et al. 2014).
Moreover, we present some anti-apoptotic molecules to-
wards the changes. Chun-hua Wan et al. demonstrated that
blockage of p53 activities with Pifithrin-α (PFT-α) and
Pifithrin-μ (PFT-μ) can reduce Mn-induced mitochondrial
H2O2 production, and the pretreatment with PFT-α and
PFT-μ has significantly weaken Mn-induced apoptosis in
PC12 cells (Wan et al. 2014). High-mobility group A1 protein
(HMGA1) is also reported as an inhibition factor. F Esposito
et al. found that with counteracting the binding of p53 to the
anti-apoptotic fact or Bcl-2, HMGA1 could inhibit p53-
mitochondrial apoptosis (Esposito et al. 2012). Moreover,
SANG KYU LEE et al. demonstrated that phosphorylation
of eIFα(eukaryotic translation initiation factors) can inhibit
the stabilization and translocation of p53 to the mitochondria,
and therefore, decreasing statin-induced apoptosis (Lee and
Kim 2013).
Mitochondria-related necrosis
p53 can regulate apoptosis. In addition, it can also regulate
necrotic cell death via the mitochondria. p53-mediated
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regulation of necrosis is associated with inner membrane
MPTP control by interacting with cyclophilin D (CypD) and
dynamin-related protein 1(Drp1). CypD is connected with
MPTP opening related to oxidative stress (Dashzeveg and
Yoshida 2015). p53 can accumulate in the inner mitochondrial
membrane, and form complexes with cyclophilin D (CypD).
This complex can mediate the inner membrane MPTP
opening.
Drp1 is a large GTPase which can control the prima-
ry mitochondrial fission. Drp1 localizes to the cyto-
plasm. When the cell is under the condition of oxidative
stress, it can bind to p53, stabilize it and play the vital
role in p53 translocation to the mitochondria. Xing Guo
et al. found that Drp1 binds to p53, thus, inducing
mitochondria-related necrosis. They used wild-type
Drp1 and Drp1 knockout mouse embryonic fibroblasts
(MEFs) and demonstrated that Drp1 stabilizes p53 and
helps to accumulate p53 on mitochondria, especially un-
der condition of oxidative stress (Guo et al. 2014).
Nurmaa Dashzeveg et al. further identified that p53 binds
to the N-terminal GTPase domain of Drp1, and Drp1 is re-
quired to assist translocation of p53 into mitochondria
(Dashzeveg and Yoshida 2015).
During the study of Drp1, a novel molecule p110 is found
which can inhibit Drp1 and p53. When treated with p110,
association of Drp1 and p53 on mitochondria were inhibited
in rats. In the experiment, p110 treatment can reduce brain
infarction in rats. And p110 can be a good molecular targeted
therapy of Huntington’s disease. Details are discussed in the
following part (Guo et al. 2014).
Novel insight of typical neurodegenerative diseases
Further studies reveal that p53 can destruct the regulation of
mitochondrial function, which contributes the abnormal neu-
ronal condition and the occurrence and development of some
neurodegenerative diseases. Based on these novel mecha-
nisms, we discuss typical neuronal diseases upon novel in-
sight of the relationship between mitochondria and p53, hop-
ing to present novel therapies towards these diseases.
Parkinson’s disease
It is now generally accepted that Parkinson’s disease (PD) is
associated with a selective loss of dopamine (DA) neurons,
especially in the substantia nigra of the midbrain (Park et al.
2015). Recent studies showed that mitochondrial dysfunction
can results in energy crises and therefore, progressive dopa-
minergic neuronal apoptosis, which is the vital cause of PD
(Hang et al. 2015).
We summarize two mainly functions of p53 and mitochon-
dria in the development of PD. As we discussed previously,
p53 can bind to Bcl-2 and release the Bax/Bak to form the
MPTP, leading into the apoptosis eventually. Moreover, Denis
Ottolini et al. found out that overexpression of p53 can dras-
tically reduce mitochondrial Ca2+ transients (recombination
of Ca2+ and sensitive photoprotein aequorin) in stimulated
cells and permit more Ca2+ released into mitochondria ma-
trix, thus, damaging mitochondrial morphology and causing
mitochondrial dysfunction. (Ottolini et al. 2013). This
Fig. 2 p53 induced apoptosis and necrosis. a The molecules and
pathway in mitochondrial p53 translocation in normal state. After
translation, Bcl-xL will bind to p53 and inhibits its function. Nuclear
p53 transactivates its target gene Puma and induce the formation of
Puma/Bcl-xL complex, which could liberate p53 in cytoplasm. MdM2
contributes to the monoubiquitination of p53, leading into the p53
degradation. b The molecules and pathway in mitochondrial p53
translocation in stress state. After the stress stimuli, mitochondrial p53
accumulation can be detected. Monoubiquitinated p53 can change into
polyubiquitination state. Polyubiquitinated p53 can switch to
deubiquitination state and translocate to the outer mitochondrial
membrane, neutralizing the inhibitory function of Bcl-2/Bcl-xL in the
presence of HAUSP. Bax and Bak can then be released and form the
MPTP, leading to the cytochrome c release, and apoptosis finally.
Besides, deubiquitination p53 can decrease inner membrane potential.
p53 can bind to cyclophilin D on inner membrane, activated cyclophilin
D contributes the inner membrane MPTP as well, leading into the
necrosis finally. Abbreviations: cc: cytochrome c, MPTP: mitochondrial
permeability transition pore. HAUSP: herpesvirus associated ubiquitin
specific protease, Bcl-2: B-cell lymphoma 2, Bcl-xL: B-cell lymphoma-
extra-large (BCL2-like 1), Bak: Bcl-2-homologous antagonist/killer, Bax:
Bcl-2-associated X protein, Puma: p53 upregulated modulator of
apoptosis, MDM2: Murine Double Minute 2
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Fig. 3 p53 and mitochondria related etiology of three neurodegenerative
diseases. Parkinson’s disease (PD) is now generally accepted that PD is
associated with a selective loss of dopamine (DA) neurons, especially in
the substantia nigra of the midbrain, p53 can bind to Bcl-2/Bcl-xL and
release the Bax/Bak to form the MPTP, leading into the apoptosis finally.
Huntington’s disease (HD) is caused by the expansion of the coding CAG
repeat in the open reading frame of the Huntingtin gene. The result of
accumulation and expression of mutated Huntingtin protein (mtHtt) will
lead to cellular dysfunctions, thus, causing HD. mtHtt binds to p53 and
upregulates nuclear p53 level as well as p53 transcriptional activity. With
the help of mtHtt, p53 binds to activated Drp1 under the stress state,
which greatly enhance the interaction of Drp1 and Fis1 on
mitochondrial outer membrane, causing the mitochondrial fission.
Besides, the interaction of Bcl-xL/Bcl-2 with p53 contributes to the
development of HD as well. Alzheimer’s disease (AD), acting the
characteristics like the progressive decline of memory and cognitive
functions as well as changes in behavior and personality. Its mechanism
is still quite unclear, but more evidences indicate that ROS and the axon
degeneration caused by mitochondrial dysfunction contribute greatly in
the process of AD. p53 will transactivate SCO2, NQO1, POX. These
factors will increase ROS generation under stress state. Besides, ROS
break p53 DNA structure and DNA-binding domain, leading into the
expression of unfolded p53, which can be marked as an early marker of
oxidative imbalance in AD patients. Accumulation of ROS result in
mitochondrial dysfunction, which functions vitally in the process of
axon degeneration. Abbreviations: mtHtt: mutated Huntingtin protein,
Drp1: dynamin-related protein 1, NQO1: quinone oxidoreductase or
NAD(P)H dehydrogenase, quinone 1, POX: proline oxidase 1
Fig. 4 Protective molecules and pathways in PD. DJ-1 is the Parkinson
disease-related protein. Its over overexpression reduces p53 expression in
transactivation and mRNA levels. The presence of DJ-1 greatly stabilizes
Mitochondrial Associated ER Membranes (MAMs) and enhances the
Ca2+ cross-talk between the two organelles. Alongside this, DJ-1 can
bind and stabilize the anti-apoptotic protein Bcl-xL, permitting its
inhibition towards Bax/Bak. PTF-μ, MPPE, Mn-SOD can inhibit p53
mitochondrial translocation and the interaction of p53/Bcl-xL.
Abbreviations: MAMs:Mitochondrial Associated ER Membranes, PTF-
μ: pifithrin-μ, MPPE: N-Methyl, N-propynyl-2-phenylethylamine, Mn-
SOD:mitochondrial superoxide dismutase
342 J Bioenerg Biomembr (2016) 48:337–347
indicates that mitochondrial dysfunction caused by p53 over-
expression is the important factor to develop PD. (Fig.3).
In the aspect of therapy, we utilize some molecules and
pathways to put forward four treating methods of
Parkinson’s disease. (Fig.4).
DJ-1 overexpression in neuroprotection
DJ-1 is the Parkinson disease-related protein, its overexpres-
sion overcomes p53-induced mitochondrial phenotypes, sug-
gesting that the protective DJ-1 role may be related to the
control of p53 turnover. Its function towards PD can be totally
divided in to three parts.
Under the stress state, DJ-1 overoverexpression reduces
p53 expression in transactivation and mRNA levels.
Moreover, the presence of DJ-1 greatly stabilizes
Mitochondrial Associated ER Membranes (MAMs) and en-
hances the Ca2+ cross-talk between the two organelles.
Alongside this, DJ-1 can bind and stabilize the anti-
apoptotic protein Bcl-xL, permitting its inhibition towards
Bax/Bak.(Ottolini et al. 2013).
Pifithrin-μ in neuroprotection
As we discussed previously, p53/Bcl-xL interaction can im-
pair mitochondrial membrane potential and balance, contrib-
uting greatly to the process of apoptosis and reducing some
pathological changes in Parkinson’s disease, Pifithrin-μ can




In PD patients, one of the factors inducing dopaminergic tox-
icity is 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Eun-
Joo Shin et al. demonstrated that N-Methyl, N-propynyl-2-
phenylethylamine (MPPE) can inhibit p53 mitochondrial
translocation and the interaction of p53/Bcl-xL in this dopa-
minergic toxicity. (Shin et al. 2015).
Mn-SOD in neuroprotection
Moreover, p53 can bind to mitochondrial Mn-SOD (SOD-2),
leading to the suppression of its superoxide scavenging activ-
ity (Zhao et al. 2005). By upregulating mitochondrial Mn-
SOD expression and UCP-2 mRNA expression, p53 toxicity
can be alleviated greatly in Parkinson’s disease.
Huntington’s disease
Huntington’s disease (HD) is caused by the expansion of the
coding CAG repeat in the open reading frame of the
Huntingtin gene The result of accumulation and expression
of mutated Huntingtin protein (mtHtt) will lead to cellular
dysfunctions, thus, causing HD (Guo et al. 2013). Besides,
recent s tudies revealed that p53 contr ibutes the
mitochondria-associated cellular dysfunction and behavioral
abnormalities in HD (Bae et al. 2005).
mtHtt with expanded polyglutamine (polyQ) binds to p53
and upregulates nuclear p53 level as well as p53 transcription-
al activity (Bae et al. 2005). We summarize two main path-
ways in overexpression of p53 contributing to the develop-
ment of HD.
The first is that mtHtt can change the balance be-
tween mitochondrial fusion and fission by regulating
p53 and Drp1.With the help of mtHtt, p53 binds to
activated Drp1 under the stress state, which greatly en-
hance the interaction of Drp1 and Fis1 on mitochondrial
outer membrane, causing the mitochondrial fission (Guo
et al. 2013, Schapira et al. 2014). Moreover, mtHtt dis-
turbs interaction between p53 with MDM2, which sta-
bilizes p53 and decreases the p53 degeneration (Bae
et al. 2005, Tsoi and Chan 2013).
Besides, the interaction of Bcl-xL/Bcl-2 with p53 still con-
tributes to the development of HD. (Fig.3).
Here are two possible treating methods of HD.
Drp1 and p110
Xing Guo et al. demonstrated that by binding to Drp1 and
mediating Drp1-induced mitochondrial and neuronal damage,
p53 contributes greatly to the development of HD pathology.
As previously discussed, p110 can inhibit necrosis.
Moreover, Xing Guo et al. revealed that with suppressing
mtHtt-induced association of p53 with mitochondria and mi-
tochondrial morphology, p110 can reduce mtHtt-induced ex-
cessive mitochondrial fragmentation, thus, improving mito-
chondrial function and cell viability in HD cell culture models
(Guo et al. 2013).
Most importantly, p110 can block the interaction between
Drp1/p53 complex and Fis1, alleviating the mitochondrial fis-
sion, and suppress the interaction of p53 and Bcl-xl or Bcl-2,
protecting cells from apoptosis (Guo et al. 2013). (Fig. 5).
Human adipose stem cells (hASC) extracts
in in neuroprotection
hASC is confirmed to be able to produce many essential
neurotrophic factors in neuronal growth and survival.
Tian Liu et al. revealed that hASC extracts can prevent
mHtt-induced apoptosis, alleviate mHtt-induced mito-
chondrial oxidative stress and recover mitochondrial
membrane potential from reduction. Interestingly,
hASC extracts can also block the interaction of p53
and mHtt, and decrease half-life of the endogenous
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p53(Liu et al. 2014). However, the exact molecule and
pathway of these effects needs to be further studied.
Alzheimer’s disease
Alzheimer’s disease (AD), acting the characters like the pro-
gressive decline of memory and cognitive functions as well as
changes in behavior and personality (Manczak et al. 2013). Its
mechanism is still quite unclear, but more evidences indicate
that ROS and the axon degeneration caused by mitochondrial
dysfunction contribute greatly in the process of AD (Fiorini
et al. 2012, Fujiwara and Morimoto 2012, 2013). Moreover,
Laura Buizza et al. confirmed that ROS/RNS contribute to
variation of p53 structure and that unfolded p53 can be
marked as an early marker of oxidative imbalance in AD
patients (Buizza et al. 2012).
Besides, more evidences suggested impaired mitochondrial
function has been shown in Alzheimer’s disease patients as
well as animal and cell models of AD (Hedskog et al. 2013).
In the central nervous system of AD patients, increasing evi-
dence indicates that mitochondrial dysfunction occurs in brain
(Mancuso et al. 2003). Decreasing of the mitochondrial cyto-
chrome c oxidase (COX) activity is the significant perfor-
mance (Mancuso et al. 2003). Besides, J. Casademont et al.
also demonstrated that defects in mitochondria like the dys-
function of electron transport chain (ETC), might play the
vital role in the AD pathological changes. It has been found
that ETC is decreased in AD brain (Casademont et al. 2003).
All these results indicated the correlation of p53 and mito-
chondria in AD development. (Fig.3).
On the aspect of treatment, we summarize five pos-
sible targeted molecular therapies towards Alzheimer’s
disease. (Fig.6).
Mitochondrial superoxide dismutase (MnSOD)
in neuroprotection
MnSOD contributes as the anti-oxidative factor and is in-
volved in the cellular defense against oxidative damage
caused by ROS (Sharma et al. 2016).
Alongside this function, Ada Fiorini et al. revealed that over-
expression of Mn-SOD can protect neurons against oxidative
damage (Fujiwara and Morimoto 2012). Overexpression of
MnSOD can inhibit p53 from combiningwith other protein like
Bcl-2, which is helpful to prevent or slow down the progression
of AD processes (Fiorini et al. 2012).
Voltage-dependent anion channel (VDAC) in neuroprotection
Maria Manczak et al. suggested that reduced voltage-
dependent anion channel 1 (VDAC1) expression may be ben-
eficial for synaptic for activity. VDAC is one of the compo-
nents in mitochondria permeability transition pore (MPTP),
the upregulation of VDAC contributes to the balance and
Fig. 5 p110 protective role in HD. p110 can block the interaction
between Drp1/p53 complex and Fis1, alleviating the mitochondrial
fission and suppress the interaction of p53 and Bcl-xl or Bcl-2, protecting
cells from apoptosis
Fig. 6 Protective molecules and pathways in AD. Mn-SOD contributes
as the anti-oxidative factor and is involved in the cellular defense against
oxidative damage caused byROS. Overexpression ofMnSOD can inhibit
p53 from combining with other protein like Bcl-2. VDAC is found to be
connected with restraining p53 under the stress state. CP-31398 is a
known compound which can rescue the p53 mutant structure and
stabilize the activation of wild-type form. Besides, CP-31,398 can
suppress mitochondrial dysfunction by increasing mitochondrial
dehydrogenase activity. PFT-α can inhibit p53 transactivation, and
result in the suppression of axon degeneration. p150Glued can inhibit
p53 transactivation and stabilize microtubule, which modulates
mitochondria function and improves axons integrity to avoid
excitotoxicity-induced degeneration. Abbreviations: VDAC: voltage-
dependent anion channel
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improvement of synaptic transmission and cell survival
(Fiorini et al. 2012),thus, improving function as well as
protecting against toxicities of AD-related genes (Manczak
et al. 2013).
Moreover, VDAC is found to be connected with p53, like
restraining p53 under the stress state (Fiorini et al. 2012).
CP-31,398 in neuroprotection
It has been demonstrated that glutamate excitotoxicity is
connected with the development in AD. Takeshi
Fujiwara et al. found that CP-31,398 can suppress glu-
tamate excitotoxicity-induced axon degeneration.
Interestingly, CP-31,398 is a known compound which
can rescue the p53 mutant structure and stabilize the
activation of wild-type form. Besides, Takeshi Fujiwara
et al. demonstrated that CP-31,398 can suppress mito-
chondrial dysfunction by increasing mitochondrial dehy-
drogenase activity compared with glutamate treatment.
However, the exact interaction and pathway of CP-
31,398 toward this effect needs further study afterwards.
(Fujiwara and Morimoto 2013).
PFT-α in neuroprotection
As we discussed previously, p53 transactivation towards Bax,
PUMA, and NOXA may lead to apoptosis. Takeshi Fujiwara
et al. found that p53 transactivation can be inhibited by PFT-α,
resulting in the suppression of axon degeneration, and this
treatment can be more efficient when treated together with
taxol. (Fujiwara and Morimoto 2012).
p150Glued in neuroprotection
p150Glued is a major component of the dynactin com-
plex. Takeshi Fujiwara et al. found out that overexpres-
sion of p150Glued can inhibit p53 transactivation and
stabilize microtubule, which modulates mitochondria
function and improve axons integri ty to avoid
excitotoxicity-induced degeneration (Fujiwara and
Morimoto 2012).
Outlook of treatment
Neuronal diseases are common but hard to cure. But we
still hold the positive opinion towards common treating
method suggested by Anthony H V Schapira et al.,
which means ablating expression, counteracting with an-
tibody fragments, enhancing the clearance towards mu-
tant or unwanted protein and correcting the abnormal
conditions. (Schapira et al. 2014) These four treating
methods might guide us into the recovery of the
neurodegenerative diseases. In this review, the molecular
therapies towards p53 and mitochondria can be classi-
fied into the four methods mentioned above, like ablat-
ing p53 expression by PFT-α in AD treating or
correcting the apoptosis condition by p110 in HD
treating. We expected that these novel molecular thera-
pies can function effectively in future clinic.
However, there is still a problem need to be resolved,
which is the opposite function of p53 in different cells
under different stress levels. As we can see in Fig. 1a,
in normal condition, p53 can maintain aerobic respira-
tory through SCO2(Fields et al. 2007). Moreover, p53
can transactivate Mieap to degenerate oxidized protein
to protect cells (Miyamoto et al. 2011). But with en-
hancement of the stress levels, p53 will lead to the
mitochondrial dysfunction and finally apoptosis.
In the p roces s o f ce l l ag ing , p53 wi l l be
overexpressed to against DNA mutation or the
Warburg effect (Matoba et al. 2006). p53 can take the
protective role by keeping or enhancing aerobic respira-
tory through SCO2 and Mieap expression to degenerate
oxidized protein under this condition. However, when
high level stress presents, p53 overexpression functions
as a detrimental role in nervous system especially in the
neurons related of neurodegenerative diseases, which ag-
gravates the symptoms of these diseases. The rank of
the stress level can then be the vital factor in the ther-
apies towards p53 and mitochondria, through which we
can determine when to increase p53 for protecting cell
or degenerate p53 for inhibiting damage. The exact
stress level rank and clear definition of p53 function
changing needs further study.
We look forward to more new and efficient treating thera-
pies from the aspect of p53 and mitochondria.
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